Current Report Filing (8-k)
2018年12月20日 - 6:28AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, DC
20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): December 19, 2018
Immune
Pharmaceuticals Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-36602
|
|
52-1841431
|
(State or other jurisdiction
of incorporation)
|
|
(SEC File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
1 Bridge Plaza North, Suite 270, Fort Lee NJ
|
|
07024
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (201) 464-2677
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.03
|
Amendments to the Articles of Incorporation or Bylaws; Change in Fiscal Year
.
|
On December 19, 2018, Immune Pharmaceuticals Inc., a Delaware
corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment
(the “Certificate of Amendment”) to its Certificate of Incorporation, increasing the total number of authorized shares
of Common Stock to 600,000,000. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated by reference
herein. The Company’s stockholders approved the Certificate of Amendment at the Company’s adjourned special meeting
of stockholders (the “Special Meeting”) on December 19, 2018.
Item 5.07
|
Submission of Matters to a Vote of Security Holders
.
|
Certain matters were submitted to a vote of stockholders at
the Special Meeting. A total of 32,853,891 shares were represented in person or by proxy at the Special Meeting, out of 49,313,329
shares outstanding and entitled to vote as of the record date. The final results for each of the matters submitted are set forth
below. Each of the proposals was approved. A more detailed description of each proposal is set forth in the Company’s Proxy
Statement filed with the Securities and Exchange Commission on November 8, 2018 (the “Proxy Statement”).
Proposal No. 1 – Amendment to Certificate of
Incorporation to Increase the Number of Authorized Shares
. The stockholders approved a proposal to amend the certificate of
incorporation of the Company (the “Certificate of Incorporation”) to increase the total number of authorized shares
of common stock to 600,000,000 by the votes set forth in the table below:
For
|
|
Against
|
|
Abstained
|
25,218,625
|
|
7,450,759
|
|
184,507
|
Proposal No. 2 – Adjournment of the Special Meeting
to solicit additional proxies if there were insufficient proxies at the Special Meeting to approve Proposal 1.
The
stockholders also approved an adjournment of the Special Meeting, if it had been necessary to solicit additional proxies, had there
been insufficient votes to approve the Certificate of Amendment,
by the votes set forth in the table below:
For
|
|
Against
|
|
Abstained
|
23,903,155
|
|
8,344,936
|
|
605,800
|
Item 9.01
|
Financial Statements and Exhibits
.
|
The exhibit listed
in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Immune Pharmaceuticals Inc.
|
|
|
|
December 19, 2018
|
By:
|
/s/ Tony Fiorino
|
|
Name:
|
Tony Fiorino, M.D., Ph.D.
|
|
Title:
|
President and Interim Chief Executive Officer
|
(USOTC:IMNPQ)
過去 株価チャート
から 5 2024 まで 6 2024
(USOTC:IMNPQ)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about (その他OTC): 0 recent articles
その他のImmune Pharmaceuticals Incニュース記事